Iovance prices $211M common stock offering at $9.15/share

IOVANCE BIOTHERAPEUTICS, INC.

Issues 23,014,000 shares at $9.15; gross proceeds ~$211M, net ~$197.1M.
Net proceeds to support AMTAGVI commercial launch, NSCLC study IOV-LUN-202, melanoma trial TILVANCE-301.
Underwriters include Jefferies, Barclays, Goldman Sachs; closing expected Feb 22, 2024.
Executive officers and directors subject to 60-day lock-up on stock sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC valued at approximately $197.1 million (effective 2024-02-20).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC
Value: approximately $197.1 million
Effective: 2024-02-20

Exact text from the filing

On February 20, 2024, Iovance Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,014,000 shares of common stock (the “Shares”) (the “Offering”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-025617

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.